Galapagos NV: business update: http://t.co/6w1jppWE
posted 4 days ago
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
Research Institute for Chromatography (R.I.C.) announces that it and its consortium partners have been awarded a grant within Eureka’s Eurostars™ program with a total budget of €1.7 million for the development of a biosimilar monoclonal antibody in a Quality by Design approach. R.I.C. will apply its chromatographic and mass spectrometric expertise throughout the project. One of the co-applicants is Bioceros BV (Utrecht, The Netherlands) that will be responsible for the monoclonal antibody generation using its proprietary CHOBC® production platform.
Eurostars is a European research and development project that can address any technological area, but must have a civilian purpose and be aimed at the development of a new product, process or service. The Eurostars project is collaborative, meaning it must involve at least two participants from two different Eurostars member countries.
The Eurostars project should be market-driven: it must have a maximum duration of three years, and within two years of project completion, the product of the research should be ready for launch onto the market. The exception to this rule applies to biomedical or medical projects, where clinical trials must be started within two years of project completion.
Flemish partners are funded through the Flemish agency for Innovation by Science and Technology (IWT).
The Research Institute for Chromatography (R.I.C.) offers chromatographic, electrophoretic and mass spectrometric support to the life sciences industry. A broad expertise, complemented with an impressive and ever expanding range of state-of-the-art instrumentation and tools, allows to handle various projects including the analysis of bio-pharmaceuticals.
Source: R.I.C.
Tags: awards
Bookmark this:
